{"id":390096,"date":"2020-11-30T18:58:04","date_gmt":"2020-11-30T23:58:04","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=390096"},"modified":"2020-11-30T18:58:04","modified_gmt":"2020-11-30T23:58:04","slug":"junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/","title":{"rendered":"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"both\">SHANGHAI, China, Dec.  01, 2020  (GLOBE NEWSWIRE) &#8212; Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the China National Medical Products Administration (NMPA) has recently accepted its Investigational New Drug (IND) application for JS006, a humanized monoclonal antibody against a human lymphocyte inhibitory receptor TIGIT.<\/p>\n<p align=\"left\">JS006 is a recombinant humanized IgG4\u03ba monoclonal antibody against human TIGIT specifically, developed independently by the Company. According to the results of pre-clinical studies, JS006 can specifically block the TIGIT-PVR pathway. TIGIT (T cell immunoglobulin and ITIM domain) is an important inhibitory receptor expressed by NK cells and T cells, which can be engaged and activated by PVR family ligands highly expressed on tumor cells and suppressive immune cells to directly inhibit the killing effect of NK cells and T cells on tumor cells. A number of pre-clinical and clinical studies showed that activation of TIGIT pathway could be a crucial underlying mechanism for the resistance to PD-1 blockade therapy. Combination of TIGIT and PD-1\/PD-L1 antibodies also showed a synergistic potential to enhance antitumor response to overcome anti-PD-1 resistance and broaden the beneficial population to immunotherapy.<\/p>\n<p align=\"both\">\n        <strong>About Junshi Biosciences<\/strong><br \/>\n        <br \/>Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R &amp; D pipeline comprising 26 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurologic, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company to obtain marketing approval for PD-1 monoclonal antibody in China and clinical trial application approval for PCSK9 monoclonal antibody from the NMPA. The world\u2019s first-in-human, first-in-class BTLA blocking antibody for solid tumors is currently in phase I clinical trials in the US and China. In early 2020, Junshi Biosciences joined forces with Institute of Microbiology Chinese Academy of Science to co-develop JS016, China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2, which has entered clinical trials and is now a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences have about 2,000 full time employees in the United States and China, including research and development centers in San Francisco, Maryland, Shanghai, Suzhou, Beijing and Guangzhou. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5UinNFuvQSei6lCjHkkV8dUbrZ4Z7VXb9rGEeDuauPZLfitRGQ__88oH142eVpvSSpeevBI_vRwx2sdK7js_U0Oa614TJtYXsu7reKluoWn7Sral4eipHWjfTWhoxSRdDWX58TXAZdOP63m1WKIuDCvFqemz8B1pxOAoGkr16nukemctSppiRN71c0f1ytGcnl7NyAzrqFCiFdjkoI91xE144qY1TZquu-MCvbiwlrhG2s2_fcMDg-WPxW6a-vARMV9oT3urSzVLYRNC5B9KzkPj88D5Cr2KPS5UtmELKwugEY34rpVRJhjUs1Jz2SliaTLHbmAud1WxuHl1suBoNjpVzI_EM57L5vVyLrJPo0yu_uvCKDd21HCvVUaAix6zCBKnHvNmPxqPPbhh5tiLceTOj9SHbx1own1eUNoWTtSL8MIy66BDpkWPU69Fz6fuRKdb_jRNN6biViWqaP8tVIxDzIUfc6XUwKqGTNloxsA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>http:\/\/junshipharma.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong><br \/>\n        <br \/>\n        <strong>IR Team:<\/strong><br \/>\n        <br \/>\n        <strong>Junshi Biosciences<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TBhh2FPs-wt5f3sQYrGUR1lJO8lTWXKRvRZjSg661qOKqhDP5txCB014G0OAlXqRfJTgczKXo9upka-BBwT06Rl0WfuVaWh_iXC0QiyniE8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@junshipharma.com<\/a><br \/>\n        <br \/>+ 86 021-2250 0300<\/p>\n<p align=\"left\">\n        <strong>Solebury Trout<\/strong><br \/>\n        <br \/>Bob Ai <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5BSXToT_IQ15vadjH7zFc6054Ofh6MBuL9Wdh3KPpJhBYYtpc9UC3mPjC3RXUUAXGk9sHsRe6cJ8ZWpqdsPHFetpUyvu2FbdLOO5ifj-W_A=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">bai@soleburytrout.com<\/a><br \/>+ 1 646.378-2926<\/p>\n<p align=\"left\">\n        <strong>PR Team:<\/strong><br \/>\n        <br \/>\n        <strong>Junshi Biosciences<\/strong><br \/>\n        <br \/>Zhi Li<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Nl1wHUjARPpZ3fFtJYPeNapfv8T5dlAyI8ng9n7Sp3LYk1NlyfARLCA8BOIww0S243ZC_mtFC5fjvBKcRNw6pqbqPVF-iOshObsEuU_tUI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">zhi_li@junshipharma.com<\/a><br \/>+ 86 021-6105 8800<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/89b09d43-a009-4d30-81dc-7eabfe8c5419\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the China National Medical Products Administration (NMPA) has recently accepted its Investigational New Drug (IND) application for JS006, a humanized monoclonal antibody against a human lymphocyte inhibitory receptor TIGIT. JS006 is a recombinant humanized IgG4\u03ba monoclonal antibody against human TIGIT specifically, developed independently by the Company. According to the results of pre-clinical studies, JS006 can specifically block the TIGIT-PVR pathway. TIGIT (T cell immunoglobulin and ITIM domain) is an important inhibitory receptor expressed by NK cells and T cells, which can be engaged and activated by PVR &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-390096","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the China National Medical Products Administration (NMPA) has recently accepted its Investigational New Drug (IND) application for JS006, a humanized monoclonal antibody against a human lymphocyte inhibitory receptor TIGIT. JS006 is a recombinant humanized IgG4\u03ba monoclonal antibody against human TIGIT specifically, developed independently by the Company. According to the results of pre-clinical studies, JS006 can specifically block the TIGIT-PVR pathway. TIGIT (T cell immunoglobulin and ITIM domain) is an important inhibitory receptor expressed by NK cells and T cells, which can be engaged and activated by PVR &hellip; Continue reading &quot;Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T23:58:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006\",\"datePublished\":\"2020-11-30T23:58:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/\"},\"wordCount\":428,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/\",\"name\":\"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=\",\"datePublished\":\"2020-11-30T23:58:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006 - Market Newsdesk","og_description":"SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) &#8212; Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the China National Medical Products Administration (NMPA) has recently accepted its Investigational New Drug (IND) application for JS006, a humanized monoclonal antibody against a human lymphocyte inhibitory receptor TIGIT. JS006 is a recombinant humanized IgG4\u03ba monoclonal antibody against human TIGIT specifically, developed independently by the Company. According to the results of pre-clinical studies, JS006 can specifically block the TIGIT-PVR pathway. TIGIT (T cell immunoglobulin and ITIM domain) is an important inhibitory receptor expressed by NK cells and T cells, which can be engaged and activated by PVR &hellip; Continue reading \"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T23:58:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006","datePublished":"2020-11-30T23:58:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/"},"wordCount":428,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/","name":"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=","datePublished":"2020-11-30T23:58:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDI0NiMzODQ5NjIyIzIxOTUzNzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/junshi-biosciences-announces-acceptance-by-nmpa-of-its-ind-application-for-js006\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/390096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=390096"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/390096\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=390096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=390096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=390096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}